Amgen will buy Micromet for $1.16 billion

01/26/2012 | Genetic Engineering & Biotechnology News

Amgen's acquisition of Micromet for $11 a share was approved by the boards of both companies. The cash transaction, worth about $1.16 billion, gives Amgen access to Micromet's antibody technology Bispecific T-cell Engager and its blood cancer drug candidate blinatumomab.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC